WO2023036820 - THERAPEUTIC USES OF 1-[2-(2,4-DIMETHYL-PHENYLSULFANYL)PHENYL]PIPERAZINE
National phase entry is expected:
Publication Number
WO/2023/036820
Publication Date
16.03.2023
International Application No.
PCT/EP2022/074860
International Filing Date
07.09.2022
Title **
[English]
THERAPEUTIC USES OF 1-[2-(2,4-DIMETHYL-PHENYLSULFANYL)PHENYL]PIPERAZINE
[French]
UTILISATIONS THÉRAPEUTIQUES DE 1-[2-(2,4-DIMÉTHYL-PHÉNYLSULFANYL)PHÉNYL]PIPÉRAZINE
Applicants **
H. LUNDBECK A/S
Inventors
EBERT, Bjarke
MCINTYRE, Roger S.
SPANNHUTH, Carsten Walter
FREIHERR VON DER GOLTZ, Christoph
Priority Data
21196078.6
10.09.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
* |
| Recordal of a Change of the Applicant's Name/Address | * |
| Type of Assignment | * |
| Applicant's Legal Status | * |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under | * |
| Patent Delivery | * |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1937 | |
| EPO | Filing, Examination, Granting | 8505 | |
| Japan | Filing, Examination, Granting | 2053 | |
| South Korea | Filing, Examination, Granting | 1815 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,050
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention provides therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine or a pharmaceutically acceptable salt thereof in the treatment of signs and symptoms of post COVID-19 syndrome or ongoing symptomatic COVID-19.[French]
L'invention concerne des utilisations thérapeutiques de 1-[2-(2,4-diméthyl-phénylsulfanyl)phényl]pipérazine ou un sel pharmaceutiquement acceptable de celle-ci dans le traitement de signes et de symptômes du syndrome post-COVID-19 ou du COVID19 symptomatique en cours.